Claroid Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 04-12-2024
- Paid Up Capital ₹ 1.50 Cr
as on 04-12-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 30.73 Cr
as on 04-12-2024
- Revenue 55.13%
(FY 2024)
- Profit 290.94%
(FY 2024)
- Ebitda 93.35%
(FY 2024)
- Net Worth 1779.59%
(FY 2024)
- Total Assets 6.54%
(FY 2024)
About Claroid Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹30.73 Cr.
Baiju Desai, Rushin Desai, Ghanshyam Patel, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24304GJ2018PLC103796
- Company No.
103796
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
31 Aug 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Claroid Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Baiju Desai  | Director | 31-Aug-2018 | Current |
| Rushin Desai | Director | 31-Aug-2018 | Current |
| Ghanshyam Patel | Director | 31-Aug-2018 | Current |
| Snehalkumar Soni | Director | 31-Aug-2018 | Current |
| Shailesh Patel | Director | 31-Aug-2018 | Current |
Financial Performance and Corporate Structure Insights of Claroid Pharmaceuticals.
Claroid Pharmaceuticals Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 55.13% increase. The company also saw a substantial improvement in profitability, with a 290.94% increase in profit. The company's net worth Soared by an impressive increase of 1779.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Claroid Pharmaceuticals?
In 2024, Claroid Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 03 Feb 2020 | ₹30.73 Cr | Open |
How Many Employees Work at Claroid Pharmaceuticals?
Claroid Pharmaceuticals has a workforce of 19 employees as of Dec 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Claroid Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Claroid Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
